FDA Would Enhance Transparency And Disclosure Of Conflicts Of Interest Of Medical Advisers – Part 1 of 3
FDA Would Enhance Transparency And Disclosure Of Conflicts Of Interest Of Medical Advisers. The US Food and Drug Administration on Wednesday proposed unknown guidelines to balm give the public more information on the experts the agency places on its all-important advisory committees, which help approve drugs and devices. The FDA has in the past been criticized for allowing individuals with at odds of interests to serve on these panels.
In some cases, prospective committee members with financial or other ties to a product under discussion can still receive special conflict of interest waivers that let their participation on an advisory panel. But on Wednesday the agency proposed new guidelines that, in its words, would “expand transparency and public disclosure” whenever one of these waivers are handed out.
FDA counselling committees provide the agency with advice on a wide range of topics, including drugs, medical devices and tobacco. They also provide key advice on regulatory decisions, such as product approvals and catholic policy matters. While the FDA is not bound to follow its committees’ recommendations, it usually does.
You must be logged in to post a comment.